Bruker (BRKR) Downgraded by Zacks Investment Research
Zacks Investment Research lowered shares of Bruker (NASDAQ:BRKR) from a buy rating to a hold rating in a report released on Tuesday morning.
According to Zacks, “Over the past three months, Bruker has been observed to trade above the broader industry. Of late, the company’s Scientific Instruments segment has been performing well where growth was driven by strong results within NANO and CALID groups. The company raising 2017 guidance, is indicative of brighter prospects. Moving on, the company’s strategic acquisition activity has been encouraging. In this context, the company recently announced the completion of acquisition of Germany-based MERLIN whose products can complement Bruker’s MALDI Biotyper platform. On the flip side, currency fluctuations, competitive landscape and macroeconomic headwinds continue to pose challenges for the company.”
Several other research firms also recently weighed in on BRKR. BTIG Research assumed coverage on shares of Bruker in a research note on Friday, January 5th. They issued a buy rating and a $42.00 target price for the company. Evercore ISI assumed coverage on shares of Bruker in a research note on Wednesday, January 3rd. They issued an in-line rating and a $36.00 target price for the company. Cowen reiterated a hold rating and issued a $35.00 target price on shares of Bruker in a research note on Thursday, December 21st. Morgan Stanley reiterated an equal weight rating and issued a $35.00 target price on shares of Bruker in a research note on Thursday, December 14th. Finally, Citigroup lifted their target price on shares of Bruker from $29.00 to $34.00 and gave the stock a neutral rating in a research note on Friday, November 3rd. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of Hold and an average price target of $32.38.
Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Thursday, November 2nd. The medical research company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.27 by $0.02. The business had revenue of $435.60 million for the quarter, compared to analyst estimates of $415.45 million. Bruker had a net margin of 8.85% and a return on equity of 25.83%. The company’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.32 earnings per share. analysts expect that Bruker will post 1.19 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which was paid on Friday, December 22nd. Stockholders of record on Monday, December 4th were paid a $0.04 dividend. The ex-dividend date of this dividend was Friday, December 1st. This represents a $0.16 annualized dividend and a dividend yield of 0.46%. Bruker’s payout ratio is 17.02%.
A number of large investors have recently modified their holdings of BRKR. AJO LP purchased a new position in Bruker during the second quarter valued at approximately $46,075,000. First Trust Advisors LP grew its stake in Bruker by 1,689.7% during the third quarter. First Trust Advisors LP now owns 502,159 shares of the medical research company’s stock valued at $14,939,000 after acquiring an additional 474,101 shares in the last quarter. Prudential Financial Inc. grew its stake in Bruker by 292.8% during the third quarter. Prudential Financial Inc. now owns 567,002 shares of the medical research company’s stock valued at $16,868,000 after acquiring an additional 422,660 shares in the last quarter. Koch Industries Inc. grew its stake in Bruker by 2,573.5% during the second quarter. Koch Industries Inc. now owns 334,774 shares of the medical research company’s stock valued at $324,000 after acquiring an additional 322,252 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new position in Bruker during the second quarter valued at approximately $6,806,000. 65.60% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Bruker (BRKR) Downgraded by Zacks Investment Research” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://theolympiareport.com/2018/01/10/bruker-brkr-downgraded-by-zacks-investment-research-2.html.
Bruker Company Profile
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.